Amryt Pharma PLC was formed in 2015 through two acquisitions, one of German firm Birken – which brought in its lead product Episalvan (AP101), and the other Som Pharmaceuticals of Switzerland – which has a next generation therapy for acromegaly and Cushing's disease in preclinical development.
Amryt made its presence known by arriving onto the London Stock Exchange's AIM market earlier this year through a reverse...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
